TheraSense Continuous Glucose Monitor R&D To Get Boost From IPO
This article was originally published in The Gray Sheet
Executive Summary
Ongoing development of TheraSense's continuous glucose monitoring system will be funded in part through a planned initial public offering of up to $115 mil. in common stock.